Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer s Q2 Revenues Inch Up 3 Percent as Income Surges 39 Percent

NEW YORK, July 27 (GenomeWeb News) - PerkinElmer yesterday reported slightly increased revenues and a boost in earnings for the second quarter of 2005.


Revenues for the quarter totaled $425.5 million, representing a 3-percent increase over last year's revenues of $412.1 million during the same period. PE's life and analytical sciences unit had $270.8 million in revenues, up 5 percent from revenues of $257.9 million during the same period last year. This growth was primarily driven by PE's genetic screening, service, and environmental businesses.


Research and development expenses were $22.9 million, up slightly from $21.5 million during the same quarter last year.


The company's net income for the quarter was $28.9 million, or $.22 per share, up from last year's $20.8 million, or $.16 per share, during the same period. This quarter's earnings included both a $14.3 million benefit from provisions for income taxes and a loss of $5.2 million from discontinued operations.


As of July 3, PerkinElmer had $158.7 million in cash and cash equivalents.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.